1st drug OK'd for movement disorder caused by certain meds
- Author: Arturo Norris Apr 13, 2017,
Apr 13, 2017, 8:33
Several other research analysts have also commented on NBIX. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision.
Neurocrine shares were up 33 percent year-to-date through Wednesday's close. Another trade for 1,625 shares valued at $66,024 was made by Grigoriadis Dimitri E. on Tuesday, January 17. Leerink Swann reiterated an outperform rating and issued a $70.00 price objective on shares of Neurocrine Biosciences in a report on Friday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. For trailing twelve months, EPS value for the stock is $-1.63.
Shares outstanding are recorded as 86.88 million and total shares floated are 86.08 million.
Shares were trading at around $4.66 apiece Wednesday. Also, CEO Kevin Charles Gorman sold 3,010 shares of the firm's stock in a transaction on Monday, February 6th. The stock was sold at an average price of $42.28, for a total transaction of $454,510.00. Creative Planning raised its stake in Neurocrine Biosciences by 0.7% in the third quarter. Corporate insiders own 4.80% of the company's stock. Opus Point Partners Management LLC acquired a new stake in Neurocrine Biosciences during the third quarter worth $206,000. Here's a quick roundup of today's bullish brokerage notes on shares of NBIX and PRTA, as well as RCII stock. The stock of Neurocrine Biosciences, Inc. Two Sigma Securities LLC bought a new stake in Neurocrine Biosciences during the third quarter worth about $212,000. Profund Advisors LLC now owns 44,422 shares of the company's stock worth $2,250,000 after buying an additional 1,377 shares in the last quarter. Following the completion of the sale, the director now directly owns 25,000 shares of the company's stock, valued at $1,057,000. The firm's 50 day moving average price is $43.86 and its 200-day moving average price is $45.23. The company has market cap of $3.56 billion. It gives investors a clue on how effective the company is in converting the money it has to invest into net income. This is an increase of approximately 879% compared to the typical daily volume of 578 put options.
Analyst actions on Wednesday included upgrades for HP (HPQ), GrubHub (GRUB), Lululemon (LULU), and a price-target hike for Neurocrine Biosciences (NBIX). Breaking that down further, it has performed 2.99% for the week, 15.00% for the month, -33.65% over the last quarter, 109.09% for the past half-year and 318.18% for this previous year. Moreover, State Of Wisconsin Inv Board has 0.01% invested in Neurocrine Biosciences, Inc.
On the ratings front, NBIX has been the subject of a number of recent research reports.
The approval was granted to San Diego-based pharmaceutical company Neurocrine Biosciences Inc (NBIX).
The Food and Drug Administration on Tuesday approved Ingrezza, developed by Neurocrine Biosciences, for treating adult patients.